semaglutide in liver cirrhosis semaglutide - Can Wegovy causeliverdamage liver Semaglutide in Liver Cirrhosis: A Promising Avenue for Treatment and Management

Semaglutideand alcoholicliverdisease The landscape of treating liver conditions, particularly liver cirrhosis, is evolving, with semaglutide emerging as a significant area of research and therapeutic interest. Initially recognized for its role in managing type 2 diabetes and facilitating weight loss, semaglutide's potential impact on liver health, especially in conditions like non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), is gaining considerable attention作者：L Saba·2025—In persons withoutcirrhosis, non-semaglutideusers had roughly twice the odds of incidentcirrhosisand 2.4 times higher odds of decompensation. In the ....

Research indicates that semaglutide can lead to substantial improvements in liver health. Studies have shown that a significant proportion of semaglutide users experienced a reduction in liver inflammation and, in some cases, a decrease in liver fat build-up.2025年5月13日—One study found thatsemaglutide helps to improve liver healthin people with metabolic dysfunction-associated steatohepatitis, a serious form ... For instance, a notable finding is that approximately 63% of semaglutide users experienced a reduction in liver inflammation without worsening scarring, a marked improvement compared to only 34% in the placebo group. Furthermore, semaglutide's effectiveness has been observed in treating liver disease, with some research suggesting it can effectively treat liver disease in two-thirds of patients作者：AI Gad·2024·被引用次数：12—Semaglutideimproves lipid profile,liversteatosis, and fibrosis parameters and reduces the BMI in T2D and obese patients with NAFLD..

The mechanism through which semaglutide benefits the liver is multifaceted. Its primary action as a GLP-1 receptor agonist aids in metabolic control, a critical factor in managing liver diseases linked to metabolic dysfunction. This includes improving cardiometabolic risk parameters such as weight management and glycemic control, which are crucial for patients with NASH cirrhosis. Beyond metabolic benefits, semaglutide has demonstrated a capacity to improve liver enzymes and reduce liver stiffness, key indicators of liver health. The molecule's potential in improving liver fibrosis has also been highlighted, with histological evaluations confirming these positive effects.2025年5月13日—One study found thatsemaglutide helps to improve liver healthin people with metabolic dysfunction-associated steatohepatitis, a serious form ...

Clinical trials have provided specific data on semaglutide's impact. For example, treatment with semaglutide for 24 weeks has been shown to significantly improve liver enzymes and reduce liver stiffness. In patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis, semaglutide has shown promise. One randomized, placebo-controlled phase 2 trial involving semaglutide (2作者：M Zasadzińska·2025—Recently, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in the treatment of MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstratedsemaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, ....4 mg once weekly) in patients with NASH-related cirrhosis has been a focal pointCirrhosis FAQs - Mayo Clinic. While some studies indicate that in patients with NASH and compensated cirrhosis, semaglutide did not significantly improve fibrosis or achieve NASH resolution compared to placebo, other research suggests broader benefits. For example, semaglutide has been found to improve lipid profiles, liver steatosis, and fibrosis parameters, while also reducing BMI in patients with T2D and obesity and NAFLD.作者：M Zasadzińska·2025—Recently, glucagon-like peptide-1 receptor agonists, particularly semaglutide, have shown emerging promise in the treatment of MASLD. Notably, the Phase III ESSENCE trial, presented in late 2024, demonstratedsemaglutide's potential in improving liver fibrosis, confirmed through histological evaluation, ...

However, it is crucial to acknowledge potential risks4492: Semaglutide in patients with NASH Cirrhosis (F4). While semaglutide is generally considered safe in patients with hepatic impairment, some individuals might experience side effects.作者：R Loomba·2023·被引用次数：463—However, in patients with cirrhosis,semaglutide did lead to improvements in cardiometabolic risk parameters(weight loss, glycaemic control, ... Notably, in patients with NASH cirrhosis who experience rapid weight loss with semaglutide, there is a noted risk of liver decompensation. This underscores the importance of careful patient selection and monitoring. Despite this, the overarching findings suggest that semaglutide offers a promising new approach for millions of patients suffering from liver disease and its associated metabolic causes作者：R Loomba·2023·被引用次数：463—However, in patients with cirrhosis,semaglutide did lead to improvements in cardiometabolic risk parameters(weight loss, glycaemic control, ....

The potential for semaglutide to prevent cirrhosis from developing is also an exciting prospect, which could halt harmful symptoms.Semaglutide therapy for metabolic dysfunction-associated... - Hepatology While more research is needed, particularly on the safety and efficacy of GLP-1 agonists in decompensated NASH cirrhosis, the current body of evidence strongly supports semaglutide's role as a therapeutic agent for various liver conditions and its potential to improve liver health.Liver disease: Diabetes and weight loss drug may be ... The drug, known by brand names like Wegovy, which promotes weight loss, is showing significant promise in alleviating liver fat build-up and inflammation, making it a critical tool in the ongoing fight against chronic liver diseases. Further studies, including retrospective cohort studies investigating the Impact of Semaglutide on Cirrhosis and its complications, are shedding more light on its long-term benefits.